Jackson, Carlayne E.School of Medicine |
|
|
After completing a Clinical Neurophysiology fellowship at UTHSCSA and beginning my career as a clinical investigator, I established my vision of establishing a comprehensive center for the management of patients with neuromuscular diseases. My goal was to develop a multidisciplinary clinic which would integrate Neurology, respiratory therapy, physical therapy and occupational therapy. Over time, these efforts led to the development of the South Texas ALS Clinic. The clinic was awarded designation by the National ALS Association as an ALS Center of Excellence in 1996 and has retained this status since that time. The clinic is currently conducted at the MARC on Wednesday afternoons and provides care for approximately 150 ALS patients and their families throughout South and Central Texas. It is one of two centers in the State of Texas and one of only 34 in the United States. The UTHSCSA ALSA Center of Excellence provides something that is difficult to find in health care today: coordinated, efficient, multi-disciplinary care centered on the person with ALS and his or her family. It offers a multidisciplinary approach to treating the disease with symptomatic relief, prevention of complications, and maintenance of optimal independence. Under my leadership, the ALS team has grown and currently includes specialists from seventeen different disciplines to help treat these patients: Neurologist; Registered Research Nurse; Respiratory Therapist; Occupational Therapist; Physical Therapist; Registered Dietician; Pastoral Care; Social Worker; Assistive Technology Specialist; Medical Equipment Specialist; Respiratory Therapy Educator; Amyotrophic Lateral Sclerosis Association South Texas Patient Services; Gastroenterologist; Pulmonologist; Orthotist; Speech Pathologist; and Psychiatrist. Together, our team develops an individualized care plan in response to each patients specific needs. The accessibility of the team for questions and help, the attention to needs and details, the ability to anticipate problems and help solve troubling billing and insurance issues, and the commitment to prepare people with ALS ahead of time for probable changes so that the are ready these all mean that no one has to feel alone on the journey. I am particularly proud of the fact that our team provides an incomparable level of expertise in ALS and is now considered one of the top ALS centers in the country.
|
|
| 4/2009 - Present | Vice President / Chief Medical Officer | UT Medicine, San Antonio, TX |
| 5/2008 - Present | Assistant Dean of Ambulatory Services | UTHSCSA, San Antonio, TX |
| 12/2007 - Present | Professor w/Tenure | UTHSCSA, Dept of Neurology, San Antonio, TX |
| 7/2007 - Present | Professor w/Tenure | UTHSCSA, Oto-Hns, San Antonio, TX |
| 7/2006 - Present | Assistant Dean and Interim Assistant Dean of Ambulatory Services | UTHSCSA, Medicine, San Antonio, TX |
| 7/1991 - Present | Staff Neurologist | Bexar County Hospital District, Medicine, San Antonio, TX |
| 7/1991 - Present | Attending Physician | Audie Murphy Veterans Administration Hospital, Medicine, San Antonio, TX |
| Year | Degree | Discipline | Institution |
| 1992 | Postdoctoral Fellowship | Neurophysiology | UTHSCSA San Antonio , TX |
| 1991 | Residency | Neurology | UTHSCSA San Antonio , TX |
| 1988 | Internship | Internal Medicine | UTHSCSA San Antonio , TX |
| 1987 | MD | Medicine | UTHSCSA San Antonio , TX |
| 1983 | BS | Chemical Engineering | Texas A&M University College Station , TX |
Neuromuscular Specialist- Clinical trials of a wide variety of potential therapies for inclusion body myositis, amyotrophic lateral sclerosis, myasthenia gravis, and peripheral neuropathy. |
| Date | Description | Institution | # Students |
| 9/2001 - Present | Intro to Clin Medicine | The University of Texas Health Science Center | |
| "Myopathy" | |||
| 9/1999 - Present | Research Neurology Select | The University of Texas Health Science Center | |
| ACES Neurology Lab | |||
| 1/1996 - Present | Clinical Medicine | The University of Texas Health Science Center | |
| South Texas ALS Clinic | |||
| 9/1994 - Present | Clinical Medicine | The University of Texas Health Science Center | |
| Neuromuscular Service Attending | |||
| 9/1993 - Present | Intro to Clin Medicine | The University of Texas Health Science Center | |
| "Amyotrophic Lateral Sclerosis" | |||
| 9/1993 - Present | Intro to Clin Medicine | The University of Texas Health Science Center | |
| "Myasthenia Gravis" | |||
| 9/1991 - Present | Clinical Medicine | The University of Texas Health Science Center | |
| Neurology Faculty Back-up Call | |||
| 9/1991 - Present | Clinical Medicine | The University of Texas Health Science Center | |
| Inpatient Consult Service, University and VA Hospitals | |||
| 1/1991 - Present | Clinical Medicine | The University of Texas Health Science Center | |
| Muscular Dystrophy Association | |||
Journal Article |
| Wagner L, Archer NP, Williamson DM, Henry JP, Schiffer R, Jackson CE. Prevalence of Amyotrophic Lateral Sclerosis in Texas, 1998-2003 Texas Medicine 2012 May;108(5). |
| Rose MR, Sadjadi R, Weinman J, Akhtar T, Pandya S, Kissel JT, Jackson CE; the Muscle Study Group. Role of Disease Severity, Illness Perceptions and Mood On Quality of Life In Muscle Disease Muscle Nerve 2012 Jan;46(3):351-359. |
| Sadjadi R, Vincent KA, Carr AJ, Walburn J, Brooks VL, Pandya S, Kissel JT, Jackson CE, Rose MR and Muscle Study Group. Validation Of The Individualised Neuromuscular Quality Of Life For The USA With Comparison Of The Impact Of Muscle Disease On Those Living In USA Versus UK Health and Qualitly of Life Outcomes 2011 Dec;9(1). |
| Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz & Valentin K Gribkoff and the Northeast ALS Consortium. The Effects of Dexpramipexole (KNS-760704) In Individuals With Amyotrophic Lateral Sclerosis Nature Medicine 2011 Dec;17(12). |
| Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, Smimow AM, Thornton CA, Moxley RT 3rd. Open-Label Trial of Recombinant Human Insulin-Like Growth Factor 1/Recombinant Human Insulin-Like Growth Factor Binding Protein 2 In Myotonic Dystrophy Type 1 Arch Neurol 2011 Jan;68(1):37-44. |
| Jackson CE. Validation Of The Individualised Neuromuscular Quality Of Life For The USA With Comparison Of The Impact Of Muscle Disease On Those Living In USA Versus UK Neurology 2011 Jan;258:1581-1592. |
| Simpson CB, May LS, Green JK, Eller RL, Jackson CE. Vibratory Asymmetry In Mobile Vocal Folds: Is It Predictive Of Vocal Fold Paresis? Annals of Otology, Rhinology and Laryngology 2011 Jan;120:239-242. |
| Miller RG, Jackson CE, Kasarksi EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoemsith C, Strong MJ, Woolley-Levine S, and the ALS Practice Parameter Task Force. Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 2009 Oct;73(15):1218-1226. |
| Miller RG, Jackson CE, Kasarksi EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoemsith C, Strong MJ, Woolley-Levine S, and the ALS Practice Parameter Task Force. Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis: Multidisciplinary Care, Symptom Management, and Cognitive/Behavioral Impairment (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the Americ Neurology 2009 Oct;73(15):1227-1233. |
| Kaufmann P, Thompson JL, Gilberto-Levy, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Kourosh-Rezania, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B, the QALS Study Group. Phase II Trial of CoQ10 For ALS Finds Insufficient Evidence To Justify Phase III Annals of Neurology 2009 Aug;66(2):235-244. |
| Lou JS, Moore D, Gordon PH, Miller R, Minocycline Study Group. Correlates of Quality of Life in ALS Amyotrophic Lateral Sclerosis 2009 Jun;23:1-6. |
| Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, McVey A, Kittrell PP, King R, Herbelin L. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients Muscle Nerve 2009 Feb;39(2):137-143. |
| Jackson CE, Rosenfeld J, Gronseth G, Barohn RJ, Dubinsky R, Simpson CB, McVey A, Kittrell P, King R, Herbelin L, and the Muscle Study Group. Randomized Double-Blind Study of Botulinum ToxinType B For Sialorrhea In ALS Patients Muscle & Nerve 2009 Feb;39(2):137-143. |
| Wolfe GE, Barohn RJ, Sanders DB, McDermott MP, and the Muscle Study Group. Comparison of Outcome Measures From A Trial of Mycophenolate Mofetil In Myasthenia Gravis Muscle & Nerve 2008 Nov;38(5):1429-1433. |
| Buchsbaum R, Kaufmann P, Barsdorf AI, Arbing R, Montes J, JLP Thompson, QALS Study Group. Web-based Data Management for a Phase II Clinical Trial in ALS Amyotrophic Lateral Sclerosis 2008 Sep;38(2):1-16. |
| Muscle Study Group. A Trial of Mycophenalate Mofetil with Prednisone as Initial Immunotherapy in Myasthenia Gravis Neurology 2008 Aug;71(6):390-391. |
| Cudkowicz M, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland PS Wieland, Barber JR, and the Northeast ALS Consortium. Arimoclomal At Dosages Up To 300mg/day Is Well Tolerated and Safe in ALS Muscle & Nerve 2008 Jul;:837-844. |
| Jackson CE, Barohn R, Gronseth G, Pandya S, Herbelin L and the Muscle Study Group (MSG). Inclusion Body Myositis Functional Rating Scale (IBMFRS): A Reliable and Valid Measure of Disease Severity Muscle & Nerve 2008 Apr;37(4):473-476. |
| Jackson CE. A Clinical Approach to Muscle Diseases Seminars in Neurology 2008 Apr;28(1):228-240. |
| Simpson C, Cheung E, Jackson C. Vocal Fold Paresis: Clinical and Electrophysiologic Features in a Tertiary Laryngology Practice Journal of Voice 2008 Mar;23(3):396-398. |
| Mullins L, Carpentier M, Paul R, Sanders, D and the Muscle Study Group. A Disease Specific Measure of Quality of Life for Myasthenia Gravis Muscle & Nerve 2008 Jan;38(2):947-956. |
| Dunckley T, Huenteiman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, Halperin R, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, Mozaffar T, Jackson CE, Bosch P, McVey A, Dick A, Barohn R, Lomen-Hoerth C, Rosenfeld J, OConnor DT, Zhang K,, Crook R, Ryberg H, Hutton M, Katz J, Simpson EP, Mitsumoto H, Bowser R, Miller RG, Appel SH and Stephan DA. Whole-Genome Analysis of Sporadic Amyotrophic Lateral Sclerosis New England Journal of Medicine 2007 Aug;357(8):775-788. |
Book Chapter |
| Jackson CE. Neuromuscular Diseases: Disorders of the Motor Neuron and Plexus and Peripheral Nerve Disease. In: Andreoli T, Carpenter C, Griggs R, Benjamin I. Andreoli And Carpenters Cecil Essentials Of Medicine. 2009. |
Abstract |
| Shefner J, Andrews J, Bedlack R, Berry J, Goslin K, Jackson C, Kissel J, Lange D, Licht J, Mozaffar T, Pestronk A, Rosenfeld J, Wolff A, Lee J, Masonek J, Jones D, Meng L, Cedarbaum J. A Study to Evaluate Safety and Tolerability of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily, Dose-Titration Regimen; 2012 Apr. (Neurology; vol. 78, no. 1). |
| Rawson, J, Grogan P, Jackson CE, Chao W, Torres K. Early Onset Ocular, Facial and Limb Weakness with High CK; 2011 Mar. (Clinical Neuromuscular Disease; vol. 12, no. 3). |
| Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew DA, Johnston WS, Kalra S, Katz JS, Mitsumoto H, Rosnefeld J, Shoesmith C, Strong MJ, Woolley SC, The ALS Practice Parameter Task Force and The Quality Standards Subcommittee of The American Academy of Neurology. AAN Practice Parameters: What They Tell Us And What They Don''t; 2010 Nov. (Amyotrophic Lateral Sclerosis; vol. 11, no. 1). |
| Dimachkie M, Muzyka I, Barohn R, Katz J, Jackson CE, Kissel J, Zhao X-S, Wang, McVey A, Dick A, Pasnoor M, Mozaffar T, Ensrud E, Rosenfeld J. Lower Extremity Amyotrophic Diplegia: Prevalence And Pattern of Weakness; 2010 Nov. (Amyotrophic Lateral Sclerosis; vol. 11, no. 1). |
| Muzyka IM, Dimachkie MM, Barohn RJ, Katz JS, Jackson CE, Wang Y, McVey A, Pasnoor M, Mozaffar T, Dick A, Rosenfeld J. Lower Extremity Amyotrophic Diplegia (LAD): Prevalence and Pattern of Weakness; 2010 Mar. (Neurology (SUPPL 2); vol. 74, no. 9). |
| Heiman-Patterson T, Jackson CE, Sherman M, Feldman S, Mitchell M, Rollins Y, Verma A, Shefner J, Scelsa S, Newman D, Mendiondo M, Kasarskis. Results of the Non-Invasive Ventilatory (NIPPV) Arm of the PEG-NIV Pilot Study; 2009 Mar. (Neurology (suppl 3); vol. 72, no. 11). |
| Kaufmann P, Thompson J, Levy G, Barsdorf A, Buchsbaum R, Montes J, Arbing R, Vecchio D, Tierney A, Bednarz K, Battista V, Gordon P, Mitsumoto H, Levin B, WALS Study Group. Is A Phase III Trial of Coenzyme Q10 (CoQ10) for ALS Justified? Results of the Phase II Randomized Controlled Trial of CoQ10 for ALS; 2008 Apr. (Presented at the 60th Annual American Academy of Neurology Meeting, Chicago, IL. Neurology (Suppl 1; vol. 70). |
| Heiman-Patterson T, Sherman M, Mendiondo M, Rollins Y, Verma A, Jackson CE, Scelsa S, Shefner J, Newman D, Kasarskis E, ALS Nutrition/NIPPV Study Group. Do Dyspnea Scales Correlate with Pulmonary Function in ALS?; 2008 Mar. (Neurology; vol. 70, no. 11). |
| Yaltho T, Grogan P, Jackson CE. A 25 Year Old Female With Weakness and Hearing Loss; 2008 Mar. (Clinical Neuromuscular Disease; vol. 9, no. 3). |
| Jackson CE, Heiman-Patterson T, Sherman M, Mendiondo M, Rollins Y, Verma A, Shefner J, Scelsa S, Newman D, Kasarskis E, N/A ALS Nutrition/NIPPV Study Team. Factors Associated With Non-Invasive Positive Pressure Ventilation (NIPPV) Compliance In Patients With ALS/MND; 2008 Jan. (Amyotrophic Lateral Sclerosis (Suppl); vol. 9, no. 1). |
| Rosenfeld R, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelians DF, Lou JS. Creatine Monohydrate In ALS: Effects on Strength, Fatigue, Respiratory Status and ALSFRS; 2008 Jan. (Amyotrophic Lateral Sclerosis; vol. 9, no. 5). |
| Jackson CE, Rosenfeld J, Gronseth G, Barohn RJ, Dubinsky R, Simpson CB, McVey A, Kittrell P, King R, Herbelin L, and the Muscle Study Group. A Randomized, Double-Blind Study of the Safety and Efficacy of Botulinum Toxin type B (Myobloc) for Sialorrhea in Amyotrophic Lateral Sclerosis; 2007 Dec. (Presented at the 18th International ALS/MND Symposium in Toronto, Canada). |
| Heatwole C, Martens B, Quinn C, Hilbert J, Pandya S, Jackson C, Thornton C, McDermott M, Moxley R. Safety and Tolerability of Recombinant Human Insulin-Like Growth Factor 1 Complexed with IGF Binding Protein 3 (rhIGF1/IGFBP3) in Myotonic Dystrophy Type 1 (DM1); 2007 Sep. (Presented at the 6th International Myotonic Dystrophy Consortium Meeting in Milan, Italy). |
| Rose M, Weinman J, Pandya S, Jackson C, Sanders D, Kissel J, Seyedsadjadi R, Muscle Study Group. Determinants of Quality of Life In Adult Muscle Diseases; 2007 Jun. (Neuromuscular Disorders; vol. 17, no. 9-10). |
Editorial |
| Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, Mozaffar T. Correspondence Regarding: TDP-43 Proteinopathy and Motor Neuron Disease In Chronic Traumatic Encephalopathy Neuropathol Exp Neurol 2010 Jan;69:918-929. |
Other |
| Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupier E, Lou J, Ensrud E, Tan E,Goldstein JM,Katz J,Dimachkie MM,Barohn RJ, Mozaffar T. Correspondence regarding: TDP-43 Proteinopathy And Motor Neuron Disease In Chronic Traumatic Encephalopathy J Neuropathol Exp Neurol 2011 Jan;. |
Federal |
|
| Funding Agency | |
| Title | Phase II/III Randomized Controlled Trial of Arimoclomal in SOD1 Positive Familial Amyotrophic Lateral Sclerosis |
| Status | Active |
| Period | 4/2009 - Present |
| Role | Consultant |
| Grant Detail | |
| Funding Agency | |
| Title | Phase II Trial of Methotrexate in Myasthenia Gravis |
| Status | Active |
| Period | 12/2008 - 11/2012 |
| Role | Co-Investigator |
| Grant Detail | The specific aim of this study is to determine if oral methotrexate is an effective therapy for myasthenia gravis (MG) patients who are prednisone dependent. |
| Funding Agency | NINDS |
| Title | Thymectomy in Non-Thymomatous Myasthenia Gravis Patients on Prednisone |
| Status | Active |
| Period | 4/2006 - 8/2011 |
| Role | Principal Investigator |
| Grant Detail | The goal of this study is to determine if thymectomy combined with prednisone results in a greater improvement in myasthenic weakness compared with prednisone alone, results in a lower total dose of prednisone and enhances the quality of life by reducing the adverse events and symptoms associated with prednisone use. |
Private |
|
| Funding Agency | Biogen Idec Inc |
| Title | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects with Amyotrophic Lateral Sclerosis (ALS) |
| Status | Active |
| Period | 6/2012 - 5/2015 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | ALS Association |
| Title | ALS and Airway Clearance (ALSAC) Is There a Best Therapy for Airway Clearance in Patients with ALS? |
| Status | Active |
| Period | 10/2011 - 10/2013 |
| Role | Co-Investigator |
| Grant Detail | Will Rogers Respiratory Institute Grant Program |
| Funding Agency | Biogen Idec |
| Title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis Protocol Number 223AS302 |
| Status | Active |
| Period | 8/2011 - 7/2013 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | Respironics |
| Title | Validation and Usability of the E70 Device |
| Status | Active |
| Period | 7/2012 - 12/2012 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | KNOPP Neurosciences |
| Title | An Open-Label, Safety and Tolerability, Study Evaluating KNS 760704 in Patients with Amoytrophic Lateral Sclerosis (ALS) |
| Status | Active |
| Period | 7/2009 - 6/2012 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | Cytokinetics |
| Title | Cytokinetics, A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS) |
| Status | Complete |
| Period | 11/2011 - 4/2012 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | Cytokinetics |
| Title | Cytokinetics, A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way, Crossover, Pharmacokinetic And Pharmacodynamic Study Of CK-2017357 In Patients With Amyotrophic Lateral Sclerosis (ALS) |
| Status | Complete |
| Period | 9/2010 - 8/2011 |
| Role | Co-Investigator |
| Grant Detail | |
